Discover
ENSC
Ensysce Biosciences, Inc.
0.30
2 x 0.21
2 x 0.37
bid
ask
+
0.01
4.03%
2 @ 04:52 AM
0.29 -0.01 (4.28%)
| Ytd | -67.21% | |
| 1y | -86.53% |
0.29
day range
0.30
0.23
52 week range
2.75
| Open | 0.29 | Prev Close | 0.29 | Low | 0.29 | High | 0.30 | Mkt Cap | 4.64M |
| Vol | 298.13K | Avg Vol | 2.23M | EPS | -3.11 | P/E | N/A | Forward P/E | -9.08 |
| Beta | 0.64 | Short Ratio | 0.12 | Inst. Own | 22.26% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 0.32 | 200-d Avg | 1.03 | 1yr Est | 102.00 |
ENSC News
benzinga.com
Ensysce Biosciences Initiates Final State Of Its PF614-MPAR-102 Clinical Trial To Evaluate Multi-Pil
Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-sta
accessnewswire.com
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
~ ~ Advances First-in-Class, Breakthrough Therapy-Designated Opioid Engineered to Protect Against Or